Ankündigung • Oct 04
Augmedix's Stock Ceases Trading and to be Delisted from the Nasdaq Stock Market Commure, Inc. announced that it has completed the acquisition of Augmedix, Inc. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. Upon completion of the transaction, Augmedix's common stock will no longer be publicly listed, and Augmedix will become a privately held company. Reported Earnings • Aug 13
Second quarter 2024 earnings: EPS misses analyst expectations Second quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.12 loss in 2Q 2023). Revenue: US$13.7m (up 27% from 2Q 2023). Net loss: US$8.45m (loss widened 68% from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Ankündigung • Aug 06
Augmedix, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Augmedix, Inc. announced that they will report Q2, 2024 results After-Market on Aug 12, 2024 Ankündigung • Jul 21
Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million. Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million on July 19, 2024. Under the terms of the agreement, Commure will acquire all outstanding shares of Augmedix common stock for a cash consideration of $2.35 per share. The transaction is expected to be funded from Commure’s cash on hand and available liquidity. Upon completion of the transaction, Augmedix’s common stock will no longer be publicly listed, and Augmedix will become a wholly-owned subsidiary of Commure. Augmedix will be required to pay Commure a termination fee of $5.24 million, in case Augmedix terminates the transaction.
The transaction is expected to close in late Q3 or early Q4 of 2024. The transaction is subject to approval by Augmedix and Commure stockholders, antitrust approval and the satisfaction of other customary closing conditions. Augmedix’s Board of Directors unanimously approved the transaction. The board of directors of Commure have approved the agreement. Stockholders representing approximately 38% of the Augmedix’s voting power have signed the voting agreements to vote in favor of the transaction. Evercore Group L.L.C. acted as financial advisor to Augmedix and provided fairness opinion to the Augmedix' Board. John M. Rafferty and Michael G. O’Bryan of Morrison & Foerster LLP acted as legal advisor to Augmedix. Marshall P. Shaffer, P.C., Christian A. Atwood, P.C. and Dave Gusella, P.C. of Kirkland & Ellis LLP acted as legal advisor and Morgan Stanley & Co. LLC acted as financial advisor to Commure. Ankündigung • Jun 05
Augmedix, Inc. Reiterates Earnings Guidance for the Second Quarter and Full Year of 2024 Augmedix, Inc. reiterated earnings guidance for the second quarter and full year of 2024. Management continues to expect second quarter 2024 revenue to increase slightly sequentially from the first quarter of 2024, and second quarter 2024 GAAP gross margins to increase from the first quarter of 2024 by 50 to 100 basis points.For the full year of 2024, management continues to expect revenue of approximately $52 to $55 million. Ankündigung • May 30
Augmedix Appoints Alex Stinard as Chief Clinical AI Officer Augmedix announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. Dr. Stinard will leverage his clinical and technological acumen to lead the development and expansion of AI solutions that address some of the biggest challenges that impact clinicians and health systems. He will also maintain his current role as the Regional Medical Director of Emergency Medicine at HCA Healthcare in Orlando, Florida. Dr. Stinard’s role will be instrumental as Augmedix continues to improve the patient experience at the point of care, increase productivity by enhancing documentation quality, and reduce the clinician’s cognitive burden of notetaking. Leveraging his forward-thinking approach, Dr. Stinard will spearhead initiatives to elevate clinical workflows and integrate essential clinician judgment to address patient needs comprehensively. With a focus on responsible AI implementation, he will champion real-time support for doctors, enhancing both patient care and clinician experiences. Major Estimate Revision • May 20
Consensus revenue estimates fall by 13% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$61.1m to US$53.2m. Forecast losses increased from -US$0.52 to -US$0.547 per share. Healthcare Services industry in the US expected to see average net income growth of 28% next year. Consensus price target down from US$6.10 to US$3.33. Share price fell 48% to US$1.21 over the past week. Reported Earnings • May 15
First quarter 2024 earnings: EPS exceeds analyst expectations First quarter 2024 results: US$0.12 loss per share. Revenue: US$13.5m (up 40% from 1Q 2023). Net loss: US$6.50m (loss widened 24% from 1Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Ankündigung • May 15
Augmedix, Inc. Provides Revenue Guidance for the Year 2024 Augmedix, Inc. provided revenue guidance for the year 2024. For the year, the company expects to generate revenue of approximately $52 million to $55 million. Price Target Changed • May 14
Price target increased by 12% to US$6.83 Up from US$6.13, the current price target is an average from 3 analysts. New target price is 497% above last closing price of US$1.15. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$0.55 next year compared to a net loss per share of US$0.44 last year. Buy Or Sell Opportunity • May 14
Now 26% overvalued Over the last 90 days, the stock has fallen 50% to US$2.34. The fair value is estimated to be US$1.86, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 43%. Revenue is forecast to grow by 90% in 2 years. Earnings are forecast to decline by 2.7% in the next 2 years. Ankündigung • May 01
Augmedix, Inc. to Report Q1, 2024 Results on May 13, 2024 Augmedix, Inc. announced that they will report Q1, 2024 results After-Market on May 13, 2024 Ankündigung • Apr 25
Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments Augmedix announced the general availability of Augmedix Go for emergency departments (EDs), marking the launch of the industry's first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the country. The launch incorporates learnings from a pilot program with HCA Healthcare. As part of the pilot, ED physicians in four HCA Healthcare hospitals utilized Augmedix Go to automate medical documentation, with the product instantaneously drafting their medical notes from patient visits. Augmedix Go aims to improve the patient experience at the point of care, increase productivity by improving documentation quality, reduce the cognitive burden of note taking by providers, and shorten chart closure time. The clinician feedback and data garnered from the pilot supported Augmedix Go's ability to achieve these objectives. Augmedix utilizes both proprietary fine-tuned large language models (LLMs) and foundationalLLMs, including Google Cloud's MedLM's suite of medically-tuned models. These AI models are utilized across different specialties and sections of the note to deliver high quality medical documentation. Augmedix Go's user interface exposes the principal steps in its note creation process to help instill trust among clinicians. Recent Insider Transactions Derivative • Mar 31
Founder notifies of intention to sell stock Ian Shakil intends to sell 300k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of March. If the sale is conducted around the recent share price of US$4.04, it would amount to US$1.2m. Since June 2023, Ian has owned 219.66k shares directly. Company insiders have collectively bought US$191k more than they sold, via options and on-market transactions, in the last 12 months. Major Estimate Revision • Mar 25
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.453 to -US$0.523 per share. Revenue forecast unchanged at US$61.3m. Healthcare Services industry in the US expected to see average net income growth of 33% next year. Consensus price target down from US$7.00 to US$6.13. Share price rose 19% to US$3.96 over the past week. Reported Earnings • Mar 19
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Full year 2023 results: US$0.44 loss per share (improved from US$0.65 loss in FY 2022). Revenue: US$44.9m (up 45% from FY 2022). Net loss: US$19.2m (loss narrowed 22% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Ankündigung • Mar 12
Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go Augmedix announced new positive data and product enhancements for Augmedix Go, its ambient AI medical documentation product. Now supporting over 50 medical specialties, the Augmedix Go mobile app optimizes ambient AI technology to produce comprehensive draft medical notes in real time by processing the natural conversations between clinicians and patients. New data from survey responses from more than a dozen enterprise and independent healthcare organizations found that clinicians in ambulatory care settings save up to one hour or more per clinic day by using Augmedix Go. Additionally, 94% of clinicians surveyed reported that Augmedix Go helps them better focus on their patients. Augmedix Go utilizes a collection of large language models (LLMs) for different note sections, including Google Cloud’s MedLM’s suite of medically-tuned models. This collection of LLMs is used in conjunction with Augmedix’s proprietary natural language processing (NLP) and structured data sets, bringing the most powerful generative AI capabilities to the healthcare industry. By utilizing multiple models that cross-check each other, Augmedix is delivering high quality notes that instill trust among clinicians. Augmedix Go seamlessly integrates with leading EHRs, including Epic, Oracle Cerner, Meditech, and athenahealth, allowing for proper organization of previously unstructured documentation into appropriate clinical data domains. Go uses a problem-based note approach, with note content organized within the History of Present Illness (HPI) and Assessment and Plan (A&P) sections of the patient’s chart. This approach provides an effortless, intuitive note structure for easy review, unlike medical documentation products that lump note content from multiple problems into a single paragraph. As an example, to help oncologists better focus on their patients, Augmedix Go automatically generates the HPI with oncologic history, the interval history with information from the last visit, a comprehensive physical exam including the ECOG (Eastern Cooperative Oncology Group) score, and an A&P that incorporates an impression detailing the status of disease and treatment plans. Clinicians use Augmedix Go to support their individual workflows with features such as additional recordings for multiple interactions across a single patient visit. Behind the scenes, the platform stitches together the recordings to create a comprehensive and structured problem-based or visit-based note, depending on the specialty and organizational preferences. Over half of clinicians use this new feature. Ankündigung • Mar 09
Augmedix, Inc. to Report Q4, 2023 Results on Mar 18, 2024 Augmedix, Inc. announced that they will report Q4, 2023 results After-Market on Mar 18, 2024 Buy Or Sell Opportunity • Mar 08
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 38% to US$3.68. The fair value is estimated to be US$4.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 90%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 23% in the next 2 years. Ankündigung • Feb 13
Augmedix Names Tomer Levy as New Senior Vice President of Engineering Augmedix announced that Tomer Levy joined the company in January 2024 in the newly-created Senior Vice President of Engineering role. Levy brings over 20 years of experience in healthcare information technology. Throughout his career, he has delivered innovative solutions in healthcare IT to large enterprises worldwide. Prior to joining Augmedix, Levy most recently served as Senior Vice President of Research and Development at Change Healthcare. He is passionate about the adoption of cloud technologies that will define a new benchmark for simplicity, cost-effectiveness, cybersecurity, and leveraging data for improved clinical outcomes. Levy worked closely with the Google Cloud Platform team to build a transformative cloud-native solution for medical imaging that set a new standard for scale, reliability, and efficiency. Levy graduated from the executive MBA program at Tel Aviv University and earned a bachelor’s degree in computer science and economics. Buy Or Sell Opportunity • Jan 23
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 9.8% to US$5.04. The fair value is estimated to be US$4.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 90%. Revenue is forecast to grow by 96% in 2 years. Earnings are forecast to grow by 30% in the next 2 years. Ankündigung • Jan 05
Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 Augmedix, Inc. revised revenue guidance for the fourth quarter and full year ended December 31, 2023. Revenue in the fourth quarter of 2023 is expected to be approximately $12.5 million, exceeding guidance of $12.3 million, and resulting in full-year 2023 revenue of approximately $44.7 million. Price Target Changed • Nov 10
Price target increased by 7.0% to US$7.63 Up from US$7.13, the current price target is an average from 4 analysts. New target price is 41% above last closing price of US$5.40. Stock is up 278% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.65 last year. Reported Earnings • Nov 09
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: US$0.097 loss per share (improved from US$0.15 loss in 3Q 2022). Revenue: US$11.8m (up 50% from 3Q 2022). Net loss: US$4.41m (loss narrowed 20% from 3Q 2022). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. New Risk • Nov 08
New major risk - Revenue and earnings growth Earnings have declined by 4.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.4% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$16m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Ankündigung • Oct 31
Augmedix, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Augmedix, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023 Price Target Changed • Oct 23
Price target increased by 12% to US$7.13 Up from US$6.38, the current price target is an average from 4 analysts. New target price is 36% above last closing price of US$5.23. Stock is up 301% over the past year. The company is forecast to post a net loss per share of US$0.48 next year compared to a net loss per share of US$0.65 last year. Board Change • Oct 09
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Rob Faulkner was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 28
Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician Controlled Mobile App Augmedix announced the early access release of the newest product on its platform, Augmedix Go, a clinician-controlled mobile app that uses generative AI to instantaneously create a fully automated draft medical note after each patient visit. Augmedix Go harnesses proprietary natural language processing (NLP), large language models (LLMs), and structured data sets, key components of Augmedix’s tech stack. This powerful technology is utilized in a thoughtful manner to ensure comprehensive and highly accurate medical notes with appropriate guardrails that safeguard against errors. Now available under early access, Augmedix Go allows the clinician to see how the technology works in creating the medical note through a simple and intuitive interface. This innovative product offers a variety of features to support busy healthcare clinicians throughout their clinic day, including summaries of key medical events, reminders of unfinished notes, and flexibility for post-visit dictation and text editing. The technology offers output control through a multimodal interface and can be utilized in both acute and ambulatory care settings. Augmedix Go can be economically adopted and implemented quickly across hospitals and health systems. Augmedix Go allows clinicians immediate access to review, edit and approve their medical notes, and can be integrated into leading electronic health record (EHR) systems. Ankündigung • Jul 29
Augmedix, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Augmedix, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023 Ankündigung • Jun 27
Augmedix, Inc., Annual General Meeting, Jul 13, 2023 Augmedix, Inc., Annual General Meeting, Jul 13, 2023, at 09:00 Pacific Standard Time. Location: 111 Sutter Street, Suite 1300, San Francicso California United States Agenda: To elect the three Class III director nominees named in the proxy statement to board of directors; to authorize, for purposes of complying with Nasdaq Listing Rule5635(d), the issuance of shares of common stock, including shares issuable upon the exercise of warrants, pursuant to the Company's Equity Line of Credit (as defined herein) (the ELOC Issuance Proposal); to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the adjustment to the exercise price of the SVB Warrant (as defined herein) (the Warrant Exercise Price Adjustment Proposal); to ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2023; and to transact such other business. Ankündigung • Jun 13
Augmedix Establishes AI Advisory Council to Guide the Company's Continued Development of High Standard, Responsible Product Development Augmedix announced the establishment of an AI Advisory Council. The healthcare industry's adoption of AI is growing very rapidly and Augmedix is committed to harnessing the power of AI thoughtfully and responsibly to provide its customers with solutions they can trust. The Advisory Council will provide advice and guidance to the Augmedix senior leadership team on matters related to the integration of AI into the Company's product development roadmap. The AI Advisory Council will be led by Joe Marks, Ph.D., who has served as a director of the Company since 2020. Dr. Marks has established himself as a technological innovator in seven different industries over the past 30 years. His areas of expertise include AI, human-computer interaction, and computer graphics. He holds degrees in Applied Mathematics (AB) & Computer Science (SM, PhD) from Harvard University, and has co-authored more than 50 peer-reviewed articles in applied computing. Previously he was the Executive Director of Carnegie Mellon University'sCenter for Machine Learning and Health. Members of the council will include distinguished industry thought leaders from computer science, bioinformatics, digital healthcare, as well as Augmedix customers. These individuals will bring diverse expertise and perspectives from academic institutions, corporate entities from various sectors, healthcare industry associations, as well as civil society organizations associated with AI. The council will hold a variety of responsibilities, including discussing regulatory frameworks, evaluating risks and opportunities for ambient medical documentation product development, reviewing AI applications and algorithms, monitoring and addressing ethical concerns, providing strategic advice and engaging with key stakeholders. Ankündigung • Jun 12
Joseph W. Marks to Resign from the Augmedix's Board of Directors Effective on the Date of 2023 Annual Meeting of Stockholders On June 6, 2023, Joseph W. Marks notified the board of directors of Augmedix, Inc. (the “Company”) that he will resign from the Company’s board of directors effective on the date of the Company’s 2023 annual meeting of stockholders. Dr. Marks’ resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Dr. Marks plans to continue to advise the Company after his departure from the board by serving as chair of the Company’s AI advisory council, which the Company expects will be formed within the next two to three months. Ankündigung • May 13
Augmedix, Inc. Provides Revenue Guidance for the Year 2023 Augmedix, Inc. provided revenue guidance for the year 2023. Augmedix now expects at least $42 million of revenue in 2023. Ankündigung • May 09
Augmedix, Inc. to Report Q1, 2023 Results on May 12, 2023 Augmedix, Inc. announced that they will report Q1, 2023 results Pre-Market on May 12, 2023 Ankündigung • Jan 10
Augmedix, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022 Augmedix, Inc. provided revenue guidance for the fourth quarter ended December 31, 2022. The company's revenue in the fourth quarter of 2022 is expected to be within the guidance range of $8.5 million to $8.6 million. Ankündigung • Nov 16
Augmedix, Inc. announced delayed 10-Q filing On 11/15/2022, Augmedix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Ankündigung • Nov 08
Augmedix, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Augmedix, Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022 Ankündigung • Sep 07
Augmedix Launches New Service, Augmedix Prep, to Significantly Reduce Physician Chart Prep Burden Augmedix, Inc. announces the launch of Augmedix Prep, a new service that significantly reduces the burden on medical staff from preparing charts prior to a patient visit. The new service features technology that prepares a patient note structure and content for the physician based on the unique visit type and the patient’s previous medical records. Alleviating this manual task ahead of time, physicians simply review the information prior to seeing the patient, allowing them to enter the visit ready to engage with the patient. Augmedix Prep is designed to address some of the most significant issues facing healthcare providers, including reducing their workload, which can help mitigate clinician burnout and improve satisfaction, as well as allowing time back to focus on patients. Augmedix Prep captures valuable information such as patient demographics, medication changes, up-to-date medical history, imaging, labs and diagnostic results, immunization history and past medical, family, and social history. At its core, chart prep is a time-consuming administrative task that can negatively impact the patient encounter. Augmedix believes that by completing charting work prior to patient encounters, the physician will be better prepared and will offer more time in their schedule for delivering care, resulting in improved patient and provider experience and increasing patient satisfaction. Ankündigung • Sep 03
Augmedix, Inc. Announces Resignation of Gerard Van Hamel Platerink as Director On September 1, 2022, Mr. Gerard van Hamel Platerink informed the Board of Directors of Augmedix, Inc. of his decision to resign as director and Chairman of the Board, including as a member of its Compensation Committee and Chair of its Nominating and Corporate Governance Committee, effectively as of September 2, 2022. Mr. van Hamel Platerink’s resignation follows his departure from Redmile Group LLC earlier this year. Ankündigung • Aug 04
Augmedix - Trio Health - CIIC Announce the Launch of an Innovative Platform On Aug. 03, 2022, Trio Health (Trio) and Augmedix, in partnership with the Consortium of Independent Immunology Clinics (CIIC), announced the launch of an innovative platform to automate, standardize, and structure clinical patient data, right from the point of care. The Trio, Augmedix and CIIC physicians' real-world patient ecosystem deliver research-ready clinical insights and real-time disease surveillance for allergy, asthma and immunology care. Augmedix's automated medical documentation technology streams the ambient conversational interaction between CIIC physicians and their patients in real-time and integrates the data captured into Trio's real-world platform to deliver superior and consistent clinical documentation across the network. With the addition of Augmedix's services, Trio's tech-enabled CIIC real-world data registry delivers customizable services to support the entire product lifecycle, including real-time drug surveillance, retrospective and prospective analysis of patient data and accelerated identification of patients for clinical studies. Augmedix and Trio began development of this combined offering in 2019 and are pleased to offer commercial availability to healthcare systems and physician practices. Support for additional specialties is expected later this year. Ankündigung • Jul 26
Augmedix, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Augmedix, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2022 Ankündigung • Apr 26
Augmedix, Inc. to Report Q1, 2022 Results on May 09, 2022 Augmedix, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022 Ankündigung • Mar 30
Augmedix, Inc. Names William Febbo as New Member to its Board of Directors Augmedix, Inc. announced that William Febbo has joined its board of directors, effective March 28, 2022. He is currently Chief Executive Officer and Director of OptimizeRx. Mr. Febbo previously served as Chief Operating Officer of Investment Banking at Merriman Capital and Chief Executive Officer of Digital Capital Network.